IR@PKUHSC  > 北京大学深圳医院
学科主题临床医学
A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis
Li, Ting1,2; Zhu, Yuxia1,2; Fan, Shangrong1,3; Liu, Xiaoping4; Xu, Huicong4; Liang, Yiheng1
关键词vulvovaginal candidiasis terconazole fluconazole
刊名MEDICAL MYCOLOGY
2015-06-01
DOI10.1093/mmy/myv017
53期:5页:455-461
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Mycology ; Veterinary Sciences
研究领域[WOS]Mycology ; Veterinary Sciences
关键词[WOS]VULVOVAGINAL CANDIDIASIS ; BORIC-ACID ; SUSCEPTIBILITY ; CANDIDOSIS ; VAGINITIS ; GLABRATA ; GUIDELINES ; MANAGEMENT ; PATIENT ; YEASTS
英文摘要

Terconazole is a new, broad-spectrum, triazole antifungal agent. The aim of this study was to compare the efficacy and safety of a 6-day course of a terconazole vaginal suppository (80 mg) with two doses of oral fluconazole (150 mg) for the treatment of severe vulvovaginal candidiasis (SVVC). In this prospective, randomized case-control study, 140 consecutive patients with SVVC were enrolled at the Department of Obstetrics and Gynecology of Peking University Shenzhen Hospital from July 1, 2013, through June 31, 2014. Patients with SVVC, initially at a 1:1 ratio, were randomly assigned to receive treatment with either the terconazole vaginal suppository or oral fluconazole. The patients had follow-up visits at 7-14 days and 30-35 days following the last dose of therapy. The clinical cure rates in the terconazole group and the fluconazole group were, respectively, 81.0% (47/58) and 75.8% (50/66) at follow-up day 7-14 and 60.3% (35/58) and 56.1% (37/66) at day 30-35. The mycological cure rates in the two groups were, respectively, 79.3% (46/58) and 71.2% (47/66) at follow-up day 7-14 and 62.1% (36/58) and 53.0% (35/66) at day 30-35 (P > .05 for all). Local irritation was the primary adverse event associated with terconazole, whereas systemic side effects were associated with fluconazole; however, these effects were minimal. This study demonstrated that a terconazole vaginal suppository (80 mg daily for 6 days) was as effective as two dose of oral fluconazole (150 mg) in the treatment of patients with SVVC; as such, terconazole could be a choice for therapy of this disorder.

语种英语
WOS记录号WOS:000356249800004
项目编号201201001 ; JCYJ 20140415162338813
资助机构Shenzhen Science and Technology
引用统计
被引频次:3[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/58627
专题北京大学深圳医院
作者单位1.Peking Univ, Shenzhen Hosp, Dept Obstet & Gynecol, Shenzhen 518036, Peoples R China
2.Shantou Univ, Coll Med, Shantou 515041, Guangdong, Peoples R China
3.Shenzhen Key Lab Gynecol Diagnost Technol Res, Shenzhen 518036, Peoples R China
4.Peking Univ, Shenzhen Hosp, Dept Lab Sci, Shenzhen 518036, Peoples R China
推荐引用方式
GB/T 7714
Li, Ting,Zhu, Yuxia,Fan, Shangrong,et al. A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis[J]. MEDICAL MYCOLOGY,2015,53(5):455-461.
APA Li, Ting,Zhu, Yuxia,Fan, Shangrong,Liu, Xiaoping,Xu, Huicong,&Liang, Yiheng.(2015).A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis.MEDICAL MYCOLOGY,53(5),455-461.
MLA Li, Ting,et al."A randomized clinical trial of the efficacy and safety of terconazole vaginal suppository versus oral fluconazole for treating severe vulvovaginal candidiasis".MEDICAL MYCOLOGY 53.5(2015):455-461.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Li, Ting]的文章
[Zhu, Yuxia]的文章
[Fan, Shangrong]的文章
百度学术
百度学术中相似的文章
[Li, Ting]的文章
[Zhu, Yuxia]的文章
[Fan, Shangrong]的文章
必应学术
必应学术中相似的文章
[Li, Ting]的文章
[Zhu, Yuxia]的文章
[Fan, Shangrong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。